Detrimental Effect of Tight Glucose Control on CV Mortality Persists Over Nine Years
Am Fam Physician. 2017 Mar 15;95(6):online.
What is the long-term effect of intensive blood glucose control in patients with type 2 diabetes mellitus?
The initial Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, which compared standard treatment with intensive control, found that despite good intentions, cardiovascular (CV) and overall mortality are significantly higher when blood glucose levels are lower. This study, which followed patients for an additional five years, found that patients in the intensive treatment group continued to maintain lower A1C levels than patients in the standard care group; they also continued to be at increased risk of death from a CV event. (Level of Evidence = 2b)
This report is a follow-up of patients who were enrolled in the ACCORD study, which randomly assigned patients with type 2 diabetes and a high risk of CV outcomes to receive usual care or treatment aimed at intensive control of blood glucose. After the 3.7-year study, patients were followed for an additional five years to determine the long-term effect of their initial treatment. The patients were no longer on a protocol, and their treatment goals were at the discretion of their clinician, but A1C levels were still lower overall in the patients who had been in the intensive-care group. The investigators did a thorough job of keeping track of the patients, following up with 98% of them (n = 8,601) who did not experience a primary outcome or death during the original trial. Over this additional time, intensive glucose lowering did not increase or decrease the primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, CV death, death from any other cause, or overall mortality. The increased CV mortality rate seen with intensive control during the active treatment stage decreased in the subsequent years but was still higher than in the group initially treated with standard treatment (hazard ratio = 1.20; 95% confidence interval, 1.03 to 1.39; P = .02).
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions